Role of GPRC5D in R/R MM Patients
An expert briefly reviews the role of GPRC5C-targeting bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM) following four previous lines of therapy, comparing its efficacy and characteristics with other treatment options like BCMA and CAR-T therapies. She also provides insights into the benefits, risks, and potential challenges related to the access and utilization of GPRC5D-targeting bispecifics, providing a comprehensive overview of considerations in the advanced R/R MM treatment landscape.
EP: 1.Case Presentation: Clinical Decision Making in a R/R MM patient
EP: 2.Treatment Options in Late Line Relapsed/Refractory MM Patients
EP: 3.Role of GPRC5D in R/R MM Patients
EP: 4.Case Presentation: Clinical Decision Making in a Patient With R/R MM
EP: 5.Navigating Bispecific Administration: Protocols, Dosage, and Challenges in R/R MM
EP: 6.Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D Bispecific
EP: 7.Case Presentation: Clinical Decision Making for a Patient With R/R MM
EP: 8.Patient-Centric Care in R/R MM
EP: 9.Guiding Through Challenges: Insights for Caregivers of R/R MM Patients
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
